Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

During a routine wellness examination, a physician evaluates a 6565-year-old female patient with a history of postmenopausal osteoporosis. The patient reports strict adherence to her medication regimen, which consists of alendronate, calcium carbonate, and cholecalciferol, over the preceding 6060 months. She exercises regularly by participating in a local walking group and denies any recent falls, bone pain, or historical fractures. A dual-energy x-ray absorptiometry (DEXA) scan performed prior to this visit demonstrates a T-score of −2.1-2.1 at the lumbar spine and −1.9-1.9 at the femoral neck. A comparison with her initial DEXA scan from 55 years ago shows significant improvement from baseline T-scores of −2.6-2.6 and −2.4-2.4 at the respective sites. Physical examination reveals a well-appearing individual with no spinal tenderness or kyphosis. Which of the following is the most appropriate next step in managing this patient's pharmacotherapy?

  1. Discontinue alendronate and maintain the current supplementation regimenAnswer
  2. B
    Continue alendronate at the current dosage for an additional five years
  3. C
    Add raloxifene to the patient's daily medication regimen
  4. D
    Schedule a repeat dual-energy x-ray absorptiometry scan in 6 months
  5. E
    Obtain a radionuclide bone scan to screen for subclinical microfractures

Answer

Discontinue alendronate and maintain the current supplementation regimen
The correct answer is to discontinue alendronate and maintain the current supplementation regimen. The patient has completed 55 years of oral bisphosphonate therapy and is currently at low-to-moderate risk for fragility fractures (her T-scores are both >−2.5> -2.5 and she has no history of clinical fractures). Under these circumstances, the standard of care is to initiate a bisphosphonate 'drug holiday.' Bisphosphonates accumulate heavily in the bone matrix and provide continued anti-resorptive effects for years after discontinuation. A drug holiday of 33 to 55 years minimizes the cumulative risk of rare but serious adverse events associated with long-term use, such as atypical femoral fractures and osteonecrosis of the jaw, while maintaining adequate fracture protection.

Step-by-Step Solution

1
Evaluate the patient's current fracture risk based on the DEXA scan results and clinical history.
The patient has no fracture history and current T-scores are >−2.5> -2.5, placing her in a low-to-moderate risk category.
Fracture risk stratification dictates whether long-term bisphosphonate therapy should be continued or paused.
2
Determine the appropriate duration of initial bisphosphonate therapy.
The patient has completed 55 years of continuous oral alendronate therapy.
Guidelines recommend reassessing the need for oral bisphosphonates after 55 years of use due to cumulative risks.
3
Synthesize the risk profile and treatment duration to formulate a management plan.
A bisphosphonate drug holiday is indicated.
A drug holiday reduces the risk of atypical femur fractures and osteonecrosis of the jaw while residual bone-bound bisphosphonate continues to protect against osteoporotic fractures.

Key Concept

Bisphosphonate drug holidays are recommended for patients with postmenopausal osteoporosis who have completed 5 years of oral therapy and have a low-to-moderate risk of fractures (T-score > -2.5 and no history of fragility fractures).
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic